Free Trial

AstraZeneca (AZN) News Today

AstraZeneca logo
£102.54 -26.00 (-0.25%)
As of 11:55 AM Eastern
AstraZeneca PLC stock logo
AstraZeneca PLC (LON:AZN) Receives Consensus Recommendation of "Moderate Buy" from Analysts
AstraZeneca PLC (LON:AZN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the six ratings firms that are currently covering the company, MarketBeat reports. Two investment analysts have rated the stock with a hold recommendation and four have assigned a buy recommenda
AstraZeneca PLC: Result of AGM
AstraZeneca PLC stock logo
AstraZeneca (LON:AZN) Reaches New 52-Week Low - What's Next?
AstraZeneca (LON:AZN) Reaches New 12-Month Low - What's Next?
AstraZeneca PLC stock logo
AstraZeneca (LON:AZN) Stock Price Passes Above 200-Day Moving Average - Time to Sell?
AstraZeneca (LON:AZN) Stock Price Crosses Above 200-Day Moving Average - Should You Sell?
Daiichi Sankyo, AstraZeneca’s Enhertu approved in European Union
Bernstein Sticks to Their Buy Rating for AstraZeneca (AZN)
AstraZeneca announces FDA approval of Imfinzi combination
AstraZeneca PLC stock logo
Berenberg Bank Reaffirms "Buy" Rating for AstraZeneca (LON:AZN)
Berenberg Bank restated a "buy" rating and issued a GBX 140 ($1.80) price objective on shares of AstraZeneca in a research report on Wednesday.
J.P. Morgan Sticks to Their Buy Rating for AstraZeneca (AZN)
AstraZeneca announces results presented at ELCC on Tagrisso
AstraZeneca slips Monday, underperforms market
AstraZeneca to invest $2.5B in Beijing R&D and manufacturing
AstraZeneca PLC stock logo
AstraZeneca PLC (LON:AZN) Given Average Rating of "Moderate Buy" by Analysts
AstraZeneca PLC (LON:AZN - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to th
AstraZeneca (AZN) Gets a Buy from UBS
AstraZeneca PLC stock logo
AstraZeneca (LON:AZN) Stock Crosses Above 200 Day Moving Average - What's Next?
AstraZeneca (LON:AZN) Share Price Crosses Above 200-Day Moving Average - Should You Sell?
AstraZeneca announces MATTERHORN trial results
AstraZeneca PLC stock logo
AstraZeneca (LON:AZN) Receives "Buy" Rating from Shore Capital
Shore Capital restated a "buy" rating on shares of AstraZeneca in a research note on Friday.
AstraZeneca PLC stock logo
AstraZeneca (LON:AZN) Stock Price Crosses Above Two Hundred Day Moving Average - What's Next?
AstraZeneca (LON:AZN) Stock Crosses Above Two Hundred Day Moving Average - Here's Why
AstraZeneca Enhertu recommended for approval in EU by CHMP
AstraZeneca, Daiichi Sankyo’s Enhertu recommended for approval in EU
Remove Ads
Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

AZN Media Mentions By Week

AZN Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

AZN
News Sentiment

0.21

0.79

Average
Medical
News Sentiment

AZN News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

AZN Articles
This Week

7

3

AZN Articles
Average Week

Remove Ads
Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (LON:AZN) was last updated on 4/16/2025 by MarketBeat.com Staff
From Our Partners